Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03104257 · ClinicalTrials.gov registry record
The Neural Correlates of Cannabis Use
A clinical trial, sponsored by Yale University.
- Completed
- Registry status
- 162
- Enrollment target
NCT03104257: Completed study, sponsored by Yale University.
NCT03104257 is a clinical trial that has completed, run by Yale University. The registered enrollment target is 162 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03104257 has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 162 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine the temporal course of recovery of CB1R availability and neural oscillations, in cannabis-dependent individuals at baseline, following 48 hour confirmed inpatient abstinence and after four weeks confirmed abstinence. This research will also examine associations between CB1R availability, neural oscillations and cognitive function.
Primary Outcome
Change in CB1R availability (e.g. volume distribution).
Interventions
- DRUG [11-C]OMAR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2016-12 |
| Est. Completion | 2022-04-27 |
What the finished NCT03104257 record still lists
NCT03104257 is an observational study that tracks outcomes without assigning an intervention. The registered 162 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which [11-C]OMAR is the first listed.
NCT03104257 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03104257 about?
NCT03104257 is a clinical study titled "The Neural Correlates of Cannabis Use". The purpose of this research study is to determine the temporal course of recovery of CB1R availability and neural oscillations, in cannabis-dependent individuals at baseline, following 48 hour confirmed inpatient abstinence and after four weeks confirmed abstinence. This research will also examine ...
What is the current status of trial NCT03104257?
This trial is currently completed. The enrollment target is 162 participants. The study started on 2016-12. Estimated completion is 2022-04-27.
What interventions are being tested in trial NCT03104257?
The interventions under investigation include: [11-C]OMAR (DRUG).
Who is sponsoring clinical trial NCT03104257?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02347111 · 162 participants · Phase 4
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
- NCT02610426 · 162 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
- NCT05040711 · 162 participants · NA
mHealth Mindfulness With Patients With Serious Illness and Their Caregivers
- NCT05514717 · 162 participants · Phase 1
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia